{"hands_on_practices": [{"introduction": "In translational science, we rely on assays to measure surrogate endpoints, but no assay is perfectly precise, and this imprecision can distort the observed relationship between a surrogate and a true clinical endpoint. This exercise [@problem_id:5074999] guides you through a derivation of this distortion, a key concept known as the \"attenuation factor\" or \"regression dilution\". Understanding this principle is the first step toward correctly interpreting and modeling biomarker data.", "problem": "In a randomized translational study evaluating a biomarker surrogate endpoint, suppose the true surrogate $S$ relates linearly to the true clinical endpoint $T$ via the structural model $T=\\alpha+\\beta S+U$, where $U$ is an error term with $\\mathbb{E}[U]=0$, $\\operatorname{Var}(U)=\\sigma_{U}^{2}$, and $U$ is independent of $S$. The surrogate is measured with classical additive measurement error by an assay, yielding an observed surrogate $S^{\\ast}=S+\\epsilon$, where $\\epsilon \\sim N(0,\\sigma_{\\epsilon}^{2})$ is independent of $S$ and $U$. Denote $\\operatorname{Var}(S)=\\sigma_{S}^{2}$, which is finite and positive. Investigators naively regress $T$ on $S^{\\ast}$ using Ordinary Least Squares (OLS), ignoring measurement error in $S^{\\ast}$.\n\nWorking in the large-sample (population) limit and using only core definitions of covariance and variance together with the stated independence assumptions, derive the attenuation factor, defined as the ratio of the population OLS slope from regressing $T$ on $S^{\\ast}$ to the true slope $\\beta$. Express your final answer as a single closed-form analytic expression in terms of $\\sigma_{S}^{2}$ and $\\sigma_{\\epsilon}^{2}$. No rounding is required, and no units are needed.", "solution": "The problem asks for the attenuation in the estimated association between the surrogate and the true endpoint when the surrogate is measured with classical additive error. The large-sample (population) Ordinary Least Squares (OLS) slope for regressing $T$ on $S^{\\ast}$ is defined by the ratio of the covariance of the outcome and the regressor to the variance of the regressor. Specifically, if $\\tilde{\\beta}$ denotes the population OLS slope from regressing $T$ on $S^{\\ast}$, then by definition,\n$$\n\\tilde{\\beta}=\\frac{\\operatorname{Cov}(T,S^{\\ast})}{\\operatorname{Var}(S^{\\ast})}.\n$$\n\nWe use the structural model and the measurement model. The structural model is\n$$\nT=\\alpha+\\beta S+U,\n$$\nwith $\\mathbb{E}[U]=0$ and $U$ independent of $S$. The measurement model is\n$$\nS^{\\ast}=S+\\epsilon,\n$$\nwith $\\epsilon \\sim N(0,\\sigma_{\\epsilon}^{2})$ and $\\epsilon$ independent of both $S$ and $U$. Let $\\operatorname{Var}(S)=\\sigma_{S}^{2}$.\n\nFirst, compute the numerator:\n$$\n\\operatorname{Cov}(T,S^{\\ast})=\\operatorname{Cov}(\\alpha+\\beta S+U,\\,S+\\epsilon).\n$$\nUsing bilinearity and the fact that the covariance of a constant with any random variable is $0$, we have\n$$\n\\operatorname{Cov}(T,S^{\\ast})=\\operatorname{Cov}(\\beta S+U,\\,S)+\\operatorname{Cov}(\\beta S+U,\\,\\epsilon).\n$$\nAgain by bilinearity,\n$$\n\\operatorname{Cov}(T,S^{\\ast})=\\beta\\,\\operatorname{Cov}(S,S)+\\operatorname{Cov}(U,S)+\\beta\\,\\operatorname{Cov}(S,\\epsilon)+\\operatorname{Cov}(U,\\epsilon).\n$$\nBy the stated independence assumptions, $\\operatorname{Cov}(U,S)=0$, $\\operatorname{Cov}(S,\\epsilon)=0$, and $\\operatorname{Cov}(U,\\epsilon)=0$. Also, $\\operatorname{Cov}(S,S)=\\operatorname{Var}(S)=\\sigma_{S}^{2}$. Therefore,\n$$\n\\operatorname{Cov}(T,S^{\\ast})=\\beta\\,\\sigma_{S}^{2}.\n$$\n\nNext, compute the denominator $\\operatorname{Var}(S^{\\ast})$:\n$$\n\\operatorname{Var}(S^{\\ast})=\\operatorname{Var}(S+\\epsilon)=\\operatorname{Var}(S)+\\operatorname{Var}(\\epsilon)+2\\,\\operatorname{Cov}(S,\\epsilon).\n$$\nIndependence of $S$ and $\\epsilon$ implies $\\operatorname{Cov}(S,\\epsilon)=0$, so\n$$\n\\operatorname{Var}(S^{\\ast})=\\sigma_{S}^{2}+\\sigma_{\\epsilon}^{2}.\n$$\n\nTherefore, the population OLS slope of $T$ on $S^{\\ast}$ is\n$$\n\\tilde{\\beta}=\\frac{\\operatorname{Cov}(T,S^{\\ast})}{\\operatorname{Var}(S^{\\ast})}=\\frac{\\beta\\,\\sigma_{S}^{2}}{\\sigma_{S}^{2}+\\sigma_{\\epsilon}^{2}}.\n$$\n\nThe attenuation factor is defined as the ratio of the naive (error-ignored) slope to the true slope $\\beta$, namely\n$$\n\\lambda=\\frac{\\tilde{\\beta}}{\\beta}=\\frac{\\sigma_{S}^{2}}{\\sigma_{S}^{2}+\\sigma_{\\epsilon}^{2}}.\n$$\nThis expression depends only on the variance of the true surrogate and the variance of the measurement error. It lies strictly between $0$ and $1$ for $\\sigma_{S}^{2}0$ and $\\sigma_{\\epsilon}^{2}0$, reflecting attenuation toward $0$ due to measurement error. This factor is also known as the reliability ratio, but here it has been derived directly from first principles using covariance and variance definitions.", "answer": "$$\\boxed{\\frac{\\sigma_{S}^{2}}{\\sigma_{S}^{2}+\\sigma_{\\epsilon}^{2}}}$$", "id": "5074999"}, {"introduction": "Validating a surrogate endpoint requires more than just establishing a strong correlation; it demands a deep understanding of a treatment's causal pathways. A therapy might beneficially modulate a surrogate endpoint while simultaneously causing harm through an independent, off-target mechanism. This practice problem [@problem_id:5074986] uses a causal mediation framework to decompose a treatment's total effect, illustrating the critical lesson that a positive change in a surrogate does not always translate to a net clinical benefit.", "problem": "Consider a translational study evaluating a new therapy $A$ intended to reduce low-density lipoprotein cholesterol (LDL-C), a biomarker proposed as a Surrogate Endpoint (SE) $S$, for the prevention of myocardial infarction. The True Clinical Endpoint (TCE) $T$ is the one-year probability of a Major Adverse Cardiac Event (MACE). Assume a linear probability model for the TCE that is commonly used for mediation intuition in early-phase translational studies, and a simple shift model for the surrogate under treatment:\n$$\n\\Pr(T=1 \\mid A,S) \\;=\\; p_0 \\;+\\; \\beta_{A} A \\;+\\; \\beta_{\\text{tox}} A \\;+\\; \\beta_{S}\\,\\big(S - \\mu_0\\big),\n$$\n$$\nS \\;=\\; \\mu_0 \\;+\\; \\gamma_{A} A \\;+\\; \\varepsilon,\n$$\nwith $\\mathbb{E}[\\varepsilon]=0$ and $A \\in \\{0,1\\}$ indicating control ($A=0$) or therapy ($A=1$). Here, $p_0$ is the baseline risk in the control arm, $\\mu_0$ is the mean LDL-C in the control arm, $\\beta_{S}$ captures the association between LDL-C and MACE risk on the risk-difference scale, $\\beta_{A}$ is any residual on-target effect of $A$ on $T$ not mediated through $S$, and $\\beta_{\\text{tox}}$ captures an off-target toxic effect of $A$ on $T$ that is independent of $S$ (for example, pro-arrhythmic liability).\n\nSuppose the following scientifically plausible parameter values are observed in an advanced-phase biomarker-to-outcome translation:\n- Baseline event risk: $p_0 = 0.15$.\n- Control mean LDL-C: $\\mu_0 = 130$ $\\text{mg}\\cdot\\text{dL}^{-1}$.\n- Treatment shifts LDL-C downward: $\\gamma_{A} = -30$ $\\text{mg}\\cdot\\text{dL}^{-1}$.\n- Risk sensitivity to LDL-C: $\\beta_{S} = 0.003$ per $\\text{mg}\\cdot\\text{dL}^{-1}$ (interpreted additively on the risk scale).\n- Residual on-target effect not through LDL-C: $\\beta_{A} = 0$.\n- Off-target toxicity on MACE risk: $\\beta_{\\text{tox}} = 0.19$.\n\nStarting from these definitions and models, derive the marginal average treatment effect on the True Clinical Endpoint, that is, the risk difference for $T$ between $A=1$ and $A=0$,\n$$\n\\Delta_T \\;=\\; \\mathbb{E}\\big[\\Pr(T=1 \\mid A=1,S)\\big] \\;-\\; \\mathbb{E}\\big[\\Pr(T=1 \\mid A=0,S)\\big],\n$$\nand compute its numerical value. Round your answer to four significant figures and express the risk difference as a decimal fraction. Your derivation should make clear why, despite a strong improvement in the surrogate $S$ and a high proportion of treatment effect explained by $S$, the net clinical effect on $T$ can still be harmful due to the off-target term $\\beta_{\\text{tox}}$.", "solution": "The objective is to derive and compute the marginal average treatment effect on the True Clinical Endpoint (TCE), denoted by $\\Delta_T$. This quantity is defined as the difference in the expected probability of a Major Adverse Cardiac Event (MACE) between the treatment arm ($A=1$) and the control arm ($A=0$). Mathematically, this is expressed as:\n$$\n\\Delta_T = \\mathbb{E}\\big[\\Pr(T=1 \\mid A=1,S)\\big] - \\mathbb{E}\\big[\\Pr(T=1 \\mid A=0,S)\\big]\n$$\nThe expectation $\\mathbb{E}[\\cdot]$ is taken over the distribution of the Surrogate Endpoint (SE) $S$, conditional on the value of the treatment indicator $A$.\n\nThe problem provides the following models and parameter values:\nThe conditional probability of the TCE, $T$:\n$$\n\\Pr(T=1 \\mid A,S) = p_0 + \\beta_{A} A + \\beta_{\\text{tox}} A + \\beta_{S}\\,(S - \\mu_0)\n$$\nThe model for the SE, $S$:\n$$\nS = \\mu_0 + \\gamma_{A} A + \\varepsilon, \\quad \\text{with } \\mathbb{E}[\\varepsilon]=0\n$$\nThe parameter values are:\n$p_0 = 0.15$, $\\mu_0 = 130$, $\\gamma_{A} = -30$, $\\beta_{S} = 0.003$, $\\beta_{A} = 0$, and $\\beta_{\\text{tox}} = 0.19$.\n\nFirst, we will calculate the first term of $\\Delta_T$, which is the expected risk in the treatment arm ($A=1$). This involves substituting $A=1$ into the model for $\\Pr(T=1 \\mid A,S)$ and then taking the expectation over the distribution of $S$ when $A=1$.\nFor $A=1$, the conditional probability is:\n$$\n\\Pr(T=1 \\mid A=1, S) = p_0 + \\beta_{A}(1) + \\beta_{\\text{tox}}(1) + \\beta_{S}\\,(S - \\mu_0) = p_0 + \\beta_{A} + \\beta_{\\text{tox}} + \\beta_{S}\\,(S - \\mu_0)\n$$\nNow, we take the expectation of this quantity. By the linearity of expectation, we have:\n$$\n\\mathbb{E}\\big[\\Pr(T=1 \\mid A=1,S)\\big] = \\mathbb{E}\\big[p_0 + \\beta_{A} + \\beta_{\\text{tox}} + \\beta_{S}\\,(S - \\mu_0) \\mid A=1\\big]\n$$\n$$\n= p_0 + \\beta_{A} + \\beta_{\\text{tox}} + \\beta_{S}\\,\\mathbb{E}[S - \\mu_0 \\mid A=1]\n$$\n$$\n= p_0 + \\beta_{A} + \\beta_{\\text{tox}} + \\beta_{S}\\,(\\mathbb{E}[S \\mid A=1] - \\mu_0)\n$$\nTo find $\\mathbb{E}[S \\mid A=1]$, we use the model for $S$:\n$$\n\\mathbb{E}[S \\mid A=1] = \\mathbb{E}[\\mu_0 + \\gamma_{A}(1) + \\varepsilon] = \\mu_0 + \\gamma_{A} + \\mathbb{E}[\\varepsilon]\n$$\nSince $\\mathbb{E}[\\varepsilon]=0$, we have $\\mathbb{E}[S \\mid A=1] = \\mu_0 + \\gamma_{A}$. Substituting this back into the expression for the expected risk:\n$$\n\\mathbb{E}\\big[\\Pr(T=1 \\mid A=1,S)\\big] = p_0 + \\beta_{A} + \\beta_{\\text{tox}} + \\beta_{S}\\,((\\mu_0 + \\gamma_{A}) - \\mu_0)\n$$\n$$\n\\mathbb{E}\\big[\\Pr(T=1 \\mid A=1,S)\\big] = p_0 + \\beta_{A} + \\beta_{\\text{tox}} + \\beta_{S}\\gamma_{A}\n$$\n\nNext, we calculate the second term of $\\Delta_T$, the expected risk in the control arm ($A=0$). We substitute $A=0$ into the model for $\\Pr(T=1 \\mid A,S)$ and take the expectation over the distribution of $S$ when $A=0$.\nFor $A=0$, the conditional probability is:\n$$\n\\Pr(T=1 \\mid A=0, S) = p_0 + \\beta_{A}(0) + \\beta_{\\text{tox}}(0) + \\beta_{S}\\,(S - \\mu_0) = p_0 + \\beta_{S}\\,(S - \\mu_0)\n$$\nTaking the expectation:\n$$\n\\mathbb{E}\\big[\\Pr(T=1 \\mid A=0,S)\\big] = \\mathbb{E}\\big[p_0 + \\beta_{S}\\,(S - \\mu_0) \\mid A=0\\big] = p_0 + \\beta_{S}\\,(\\mathbb{E}[S \\mid A=0] - \\mu_0)\n$$\nTo find $\\mathbb{E}[S \\mid A=0]$, we use the model for $S$:\n$$\n\\mathbb{E}[S \\mid A=0] = \\mathbb{E}[\\mu_0 + \\gamma_{A}(0) + \\varepsilon] = \\mu_0 + \\mathbb{E}[\\varepsilon] = \\mu_0\n$$\nSubstituting this back:\n$$\n\\mathbb{E}\\big[\\Pr(T=1 \\mid A=0,S)\\big] = p_0 + \\beta_{S}\\,(\\mu_0 - \\mu_0) = p_0\n$$\n\nFinally, we compute $\\Delta_T$ by subtracting the expected risk in the control arm from the expected risk in the treatment arm:\n$$\n\\Delta_T = (p_0 + \\beta_{A} + \\beta_{\\text{tox}} + \\beta_{S}\\gamma_{A}) - p_0\n$$\n$$\n\\Delta_T = \\beta_{A} + \\beta_{\\text{tox}} + \\beta_{S}\\gamma_{A}\n$$\nThis expression decomposes the total average treatment effect into its constituent parts. The term $\\beta_{S}\\gamma_{A}$ represents the portion of the effect mediated through the surrogate endpoint $S$. The terms $\\beta_A$ and $\\beta_{\\text{tox}}$ represent the direct effects of the treatment on the true endpoint $T$ that are not mediated by $S$.\n\nAs requested, we can use this formula to understand why an improvement in the surrogate does not guarantee a net clinical benefit. The term $\\beta_S \\gamma_A$ represents the beneficial effect mediated by lowering LDL-C. With $\\beta_S  0$ (higher LDL-C is bad) and $\\gamma_A  0$ (treatment lowers LDL-C), this product is negative, indicating a reduction in risk. However, the term $\\beta_{\\text{tox}}$ represents an independent, harmful off-target effect. If this positive term is larger in magnitude than the beneficial mediated effect, the net effect $\\Delta_T$ will be positive, indicating an overall increase in risk and a harmful treatment.\n\nNow, we substitute the given numerical values into the derived formula:\n$\\beta_{A} = 0$, $\\beta_{\\text{tox}} = 0.19$, $\\beta_{S} = 0.003$, and $\\gamma_{A} = -30$.\n$$\n\\Delta_T = 0 + 0.19 + (0.003) \\times (-30)\n$$\n$$\n\\Delta_T = 0.19 - 0.09\n$$\n$$\n\\Delta_T = 0.10\n$$\nA positive value for $\\Delta_T$ signifies that the therapy, on average, increases the risk of a MACE. The beneficial effect mediated through the surrogate (a risk reduction of $0.09$) is more than offset by the harmful off-target toxicity (a risk increase of $0.19$), leading to a net harmful effect.\n\nThe problem asks for the answer to be rounded to four significant figures.\n$$\n\\Delta_T = 0.1000\n$$", "answer": "$$\n\\boxed{0.1000}\n$$", "id": "5074986"}, {"introduction": "Once a statistical model linking a surrogate to a true clinical endpoint is established, its real value lies in its application to decision-making. For a new therapy, how large must the effect on the surrogate be to confidently predict a meaningful benefit for patients? This final exercise [@problem_id:5075034] introduces the Surrogate Threshold Effect (STE), a powerful concept that translates a meta-analytic model into a concrete decision rule for future clinical development.", "problem": "A translational study evaluates a continuous biomarker surrogate endpoint $S$ for a patient-centered continuous true endpoint $T$, where larger positive values indicate greater clinical benefit for both $S$ and $T$. At the trial level, the treatment effect on $T$ across randomized trials is modeled as a linear random-effects meta-regression on the treatment effect on $S$:\n$$\n\\Delta_T \\;=\\; \\alpha \\;+\\; \\beta\\,\\Delta_S \\;+\\; \\varepsilon,\n$$\nwith $\\varepsilon \\sim \\mathcal{N}(0,\\tau^{2})$ representing between-trial heterogeneity. The parameters are estimated from $K$ independent trials, yielding $\\hat{\\alpha}$ and $\\hat{\\beta}$ with large-sample joint normality, and the following estimated quantities:\n- $\\hat{\\alpha} = 0.05$,\n- $\\hat{\\beta} = 0.80$,\n- $\\operatorname{Var}(\\hat{\\alpha}) = 0.0025$,\n- $\\operatorname{Var}(\\hat{\\beta}) = 0.04$,\n- $\\operatorname{Cov}(\\hat{\\alpha},\\hat{\\beta}) = -0.005$,\n- $\\hat{\\tau}^{2} = 0.04$.\n\nAssume the Studentâ€™s $t$ distribution with $\\nu = 18$ degrees of freedom approximates the predictive uncertainty for a new trial and use the two-sided $0.95$ critical value $t_{0.975,18} = 2.101$. Define the Surrogate Threshold Effect (STE) as the smallest value $s^{\\star}$ of the surrogate effect $\\Delta_S$ such that the lower bound of the $0.95$ predictive interval for the new-trial true effect $\\Delta_T$ at $\\Delta_S = s^{\\star}$ is strictly greater than $0$.\n\nA new treatment shows an observed surrogate effect $s_{\\text{obs}} = 0.55$ in standard deviation units. Compute the STE $s^{\\star}$ under the model and assumptions above. Express your answer in standard deviation units. Round your answer to four significant figures.", "solution": "The objective is to compute the Surrogate Threshold Effect, $s^{\\star}$. This is the value of the surrogate effect $\\Delta_S$ for which the lower limit of the $0.95$ predictive interval for the true effect $\\Delta_T$ is equal to $0$.\n\nFor a new trial with a given surrogate effect $\\Delta_S$, the predicted true effect is given by the fitted regression line:\n$$\n\\hat{\\Delta}_T(\\Delta_S) = \\hat{\\alpha} + \\hat{\\beta}\\Delta_S\n$$\nA $0.95$ predictive interval for the true effect in this new trial, $\\Delta_{T, \\text{new}}$, is given by:\n$$\n\\hat{\\Delta}_T(\\Delta_S) \\pm t_{0.975, \\nu} \\times \\text{SE}(\\text{prediction})\n$$\nwhere $\\text{SE}(\\text{prediction})$ is the standard error of the prediction. This standard error accounts for two sources of uncertainty:\n1. The uncertainty in the estimated regression parameters ($\\hat{\\alpha}$ and $\\hat{\\beta}$).\n2. The inherent between-trial variability, represented by $\\tau^2$.\n\nThe variance of the prediction error, $\\hat{\\Delta}_T - \\Delta_{T, \\text{new}}$, is the sum of the variance of the fitted value and the between-trial variance:\n$$\n\\text{Var}(\\text{prediction}) = \\text{Var}(\\hat{\\alpha} + \\hat{\\beta}\\Delta_S) + \\tau^2\n$$\nThe variance of the linear combination $\\hat{\\alpha} + \\hat{\\beta}\\Delta_S$ is:\n$$\n\\text{Var}(\\hat{\\alpha} + \\hat{\\beta}\\Delta_S) = \\text{Var}(\\hat{\\alpha}) + (\\Delta_S)^2 \\text{Var}(\\hat{\\beta}) + 2\\Delta_S \\text{Cov}(\\hat{\\alpha}, \\hat{\\beta})\n$$\nCombining these and using the estimated values, the squared standard error of prediction is:\n$$\n\\left(\\text{SE}(\\text{prediction})\\right)^2 = \\operatorname{Var}(\\hat{\\alpha}) + (\\Delta_S)^2 \\operatorname{Var}(\\hat{\\beta}) + 2\\Delta_S \\operatorname{Cov}(\\hat{\\alpha}, \\hat{\\beta}) + \\hat{\\tau}^2\n$$\nThe lower bound of the $0.95$ predictive interval is:\n$$\nL(\\Delta_S) = (\\hat{\\alpha} + \\hat{\\beta}\\Delta_S) - t_{0.975, \\nu} \\sqrt{\\operatorname{Var}(\\hat{\\alpha}) + (\\Delta_S)^2 \\operatorname{Var}(\\hat{\\beta}) + 2\\Delta_S \\operatorname{Cov}(\\hat{\\alpha}, \\hat{\\beta}) + \\hat{\\tau}^2}\n$$\nThe STE, $s^{\\star}$, is found by setting this lower bound to $0$:\n$$\n\\hat{\\alpha} + \\hat{\\beta}s^{\\star} = t_{0.975, \\nu} \\sqrt{\\operatorname{Var}(\\hat{\\alpha}) + (s^{\\star})^2 \\operatorname{Var}(\\hat{\\beta}) + 2s^{\\star} \\operatorname{Cov}(\\hat{\\alpha}, \\hat{\\beta}) + \\hat{\\tau}^2}\n$$\nTo solve for $s^{\\star}$, we square both sides. This is valid as long as $\\hat{\\alpha} + \\hat{\\beta}s^{\\star}  0$, which is expected for a meaningful threshold where the effect becomes positive.\n$$\n(\\hat{\\alpha} + \\hat{\\beta}s^{\\star})^2 = (t_{0.975, \\nu})^2 \\left( \\operatorname{Var}(\\hat{\\alpha}) + (s^{\\star})^2 \\operatorname{Var}(\\hat{\\beta}) + 2s^{\\star} \\operatorname{Cov}(\\hat{\\alpha}, \\hat{\\beta}) + \\hat{\\tau}^2 \\right)\n$$\nExpanding and collecting terms in powers of $s^{\\star}$ yields a quadratic equation of the form $A(s^{\\star})^2 + B s^{\\star} + C = 0$.\nLet $t = t_{0.975, 18}$.\n$$\n\\hat{\\alpha}^2 + 2\\hat{\\alpha}\\hat{\\beta}s^{\\star} + \\hat{\\beta}^2(s^{\\star})^2 = t^2\\operatorname{Var}(\\hat{\\alpha}) + t^2\\operatorname{Var}(\\hat{\\beta})(s^{\\star})^2 + 2t^2\\operatorname{Cov}(\\hat{\\alpha}, \\hat{\\beta})s^{\\star} + t^2\\hat{\\tau}^2\n$$\nRearranging gives:\n$$\n\\left(\\hat{\\beta}^2 - t^2\\operatorname{Var}(\\hat{\\beta})\\right)(s^{\\star})^2 + \\left(2\\hat{\\alpha}\\hat{\\beta} - 2t^2\\operatorname{Cov}(\\hat{\\alpha}, \\hat{\\beta})\\right)s^{\\star} + \\left(\\hat{\\alpha}^2 - t^2(\\operatorname{Var}(\\hat{\\alpha}) + \\hat{\\tau}^2)\\right) = 0\n$$\nThe coefficients are:\n$$\nA = \\hat{\\beta}^2 - t^2\\operatorname{Var}(\\hat{\\beta})\n$$\n$$\nB = 2(\\hat{\\alpha}\\hat{\\beta} - t^2\\operatorname{Cov}(\\hat{\\alpha}, \\hat{\\beta}))\n$$\n$$\nC = \\hat{\\alpha}^2 - t^2(\\operatorname{Var}(\\hat{\\alpha}) + \\hat{\\tau}^2)\n$$\nWe substitute the given values:\n- $\\hat{\\alpha} = 0.05$\n- $\\hat{\\beta} = 0.80$\n- $\\operatorname{Var}(\\hat{\\alpha}) = 0.0025$\n- $\\operatorname{Var}(\\hat{\\beta}) = 0.04$\n- $\\operatorname{Cov}(\\hat{\\alpha},\\hat{\\beta}) = -0.005$\n- $\\hat{\\tau}^{2} = 0.04$\n- $t = 2.101 \\implies t^2 \\approx 4.414201$\n\nNow, we compute the coefficients $A$, $B$, and $C$:\n$$\nA = (0.80)^2 - (4.414201)(0.04) = 0.64 - 0.17656804 = 0.46343196\n$$\n$$\nB = 2((0.05)(0.80) - (4.414201)(-0.005)) = 2(0.04 + 0.022071005) = 2(0.062071005) = 0.12414201\n$$\n$$\nC = (0.05)^2 - 4.414201(0.0025 + 0.04) = 0.0025 - 4.414201(0.0425) = 0.0025 - 0.1876035425 = -0.1851035425\n$$\nWe solve the quadratic equation $A(s^{\\star})^2 + Bs^{\\star} + C = 0$ using the quadratic formula $s^{\\star} = \\frac{-B \\pm \\sqrt{B^2 - 4AC}}{2A}$.\nFirst, we calculate the discriminant $D = B^2 - 4AC$:\n$$\nD = (0.12414201)^2 - 4(0.46343196)(-0.1851035425) \\approx 0.015411258 - (-0.343133306) = 0.358544564\n$$\n$$\n\\sqrt{D} \\approx \\sqrt{0.358544564} \\approx 0.598785909\n$$\nThe two possible solutions for $s^{\\star}$ are:\n$$\ns^{\\star}_{1} = \\frac{-0.12414201 + 0.598785909}{2(0.46343196)} = \\frac{0.474643899}{0.92686392} \\approx 0.5120835\n$$\n$$\ns^{\\star}_{2} = \\frac{-0.12414201 - 0.598785909}{2(0.46343196)} = \\frac{-0.722927919}{0.92686392} \\approx -0.7800004\n$$\nTo select the correct root, we recall the initial condition $\\hat{\\alpha} + \\hat{\\beta}s^{\\star}  0$.\nFor $s^{\\star}_{1} \\approx 0.512$: $\\hat{\\alpha} + \\hat{\\beta}s^{\\star}_{1} = 0.05 + 0.80(0.5120835) \\approx 0.05 + 0.4096668 \\approx 0.4596668  0$. This root is valid.\nFor $s^{\\star}_{2} \\approx -0.780$: $\\hat{\\alpha} + \\hat{\\beta}s^{\\star}_{2} = 0.05 + 0.80(-0.7800004) \\approx 0.05 - 0.62400032 \\approx -0.57400032  0$. This root corresponds to the case where the upper bound of the predictive interval is zero, not the lower bound.\nTherefore, the correct solution is $s^{\\star} = s^{\\star}_{1}$.\n\nThe definition of STE is the smallest value of $\\Delta_S$ such that the lower bound is strictly greater than $0$. We have found the value $s^{\\star}$ where the lower bound is exactly $0$. Since the lower bound function $L(\\Delta_S)$ can be shown to be increasing at $s^{\\star}$, any value of $\\Delta_S  s^{\\star}$ will result in a lower bound greater than $0$. Thus, $s^{\\star}$ is the threshold.\n\nThe problem requires the answer to be rounded to four significant figures.\n$$\ns^{\\star} \\approx 0.5120835\n$$\nRounding to four significant figures, we get $0.5121$.\nThe given value $s_{\\text{obs}} = 0.55$ is for evaluation of a new treatment (since $0.55  0.5121$, this new treatment would be considered effective based on the STE criteria), but it is not needed for the calculation of the STE itself.", "answer": "$$\\boxed{0.5121}$$", "id": "5075034"}]}